- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Cognitive remediation training, Nicotine polacrilex lozenge
- Behavioral · Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1033–1056
of 33,158
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pompe Disease
- Interventions
- Albuterol, Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- HIV Lipodystrophy
- Interventions
- mecasermin, Placebo control
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Asthma
- Interventions
- Fluticasone Propionate 100mcg via ACCUHALER/DISKUS, GSK2190915 100mg, GSK2190915 10mg, GSK2190915 300mg, GSK2190915 30mg, Montelukast 10mg, Placebo GSK2190915 one tablet, Placebo montelukast, Placebo fluticasone propionate via ACCUHALER/DISKUS, Placebo GSK2190915 two tablets
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Huntington Beach, California • Newport Beach, California + 19 more
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Foralumab, Placebo
- Drug · Other
- Lead sponsor
- Tiziana Life Sciences LTD
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- North Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 4 more
- Conditions
- Dementia, Behavior Problems
- Interventions
- TREA (Treatment Routes for Exploring Agitation), Placebo Control Group
- Behavioral
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 60 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic, C-Reactive Protein, High Sensitivity C-Reactive Protein, Hs-CRP, hsCRP
- Interventions
- TOUR006 - 50 MG, TOUR006 - 25 MG, TOUR006 - 15 MG, Placebo
- Drug · Other
- Lead sponsor
- Tourmaline Bio, Inc., a Novartis Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 32 more
- Conditions
- HIV, HIV Infections
- Interventions
- Stribild, Atripla, Stribild Placebo, Atripla Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 707 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 63 more
- Conditions
- Diabetes, Hypertension
- Interventions
- Quinapril (Accupril) plus Alpha Lipoic Acid, accupril, placebo, accupril, alpha lipoic acid
- Drug
- Lead sponsor
- InVasc Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Tucker, Georgia
- Conditions
- Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
- Interventions
- Gilteritinib, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 6
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Chicago, Illinois + 3 more
- Conditions
- Zika Virus
- Interventions
- Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml), Single dose of placebo via subcutaneous injection (0.5ml)., Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Burlington, Vermont
- Conditions
- Allergic Asthma
- Interventions
- gamma tocopherol, Placebo
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Parkinson's Disease
- Interventions
- ADX48621, Placebo
- Drug
- Lead sponsor
- Addex Pharma S.A.
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 10 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Placebo ELLIPTA device, Placebo capsules for use in HANDIHALER device, Inhaler Preference Questionnaire Version 1, Inhaler Preference Questionnaire Version 2
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 22
- States / cities
- Glendale, Arizona • Clearwater, Florida • Orlando, Florida + 19 more
- Conditions
- Crohn's Disease
- Interventions
- Andecaliximab, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 33
- States / cities
- Dothan, Alabama • Scottsdale, Arizona • Los Angeles, California + 30 more
- Conditions
- Asthma
- Interventions
- Placebo Q2W, Tralokinumab 300 mg, Q2W, Placebo, Q2/4W, Tralokinumab 300 mg, Q2/4W
- Other · Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 11
- States / cities
- Rancho Mirage, California • Centennial, Colorado • New Haven, Connecticut + 8 more
- Conditions
- Maintenance of Smoking Cessation
- Interventions
- rimonabant (SR141716)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Myocardial Infarct
- Interventions
- RNS60, Placebo
- Drug
- Lead sponsor
- Revalesio Corporation
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Atopic Dermatitis, Eczema
- Interventions
- Lebrikizumab, Placebo, Topical Corticosteroid (TCS)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more
- Conditions
- Necrotizing Enterocolitis
- Interventions
- hydrocortisone, placebo
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 0 Days to 6 Months
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Evanston, Illinois
- Conditions
- Healthy
- Interventions
- Vitamin D3
- Dietary Supplement
- Lead sponsor
- University of Georgia
- Other
- Eligibility
- 9 Years to 13 Years
- Enrollment
- 323 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Athens, Georgia • Indianapolis, Indiana • West Lafayette, Indiana
- Conditions
- Peripheral Arterial Disease
- Interventions
- Bupivacaine liposome, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Eau Claire, Wisconsin
- Conditions
- HIV Infections, Neuropathic Pain, Cannabis
- Interventions
- Receipt of Coupon for Placebo Soft-Gel Capsule, Receipt of Coupon for High THC Soft-Gel Capsule, Receipt of Coupon for Equal THC and CBD Soft-Gel Capsule, Receipt of Coupon for High CBD Soft-Gel Capsule
- Other
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- The Bronx, New York